

1.	<p>Treatment & Condition</p> <p>Atezolizumab with nab-paclitaxel for untreated PDL1-positive, locally advanced or metastatic, triple-negative breast cancer</p>																		
2.	<p>Associated appraisal body & Summary of ruling</p> <p>NICE Technology Appraisal guidance TA639 (July 2020)</p> <p>Atezolizumab (Tecentriq®) with nab-paclitaxel is recommended, within its marketing authorisation, for treating triple-negative, unresectable, locally advanced or metastatic breast cancer in adults whose tumours express PD-L1 at a level of 1% or more and who have not had previous chemotherapy for metastatic disease. It is recommended only if the company provides atezolizumab according to the commercial arrangement.</p>																		
3.	<p>Number of people in Northern Ireland expected to take up service/therapy</p> <p>According to the Resource Impact Template that accompanies NICE TA639, the number of people in Northern Ireland estimated to take up treatment with atezolizumab in line with this guidance is as follows:</p> <table border="1" data-bbox="260 1111 1417 1283"> <thead> <tr> <th colspan="6">Estimated number of people treated in Northern Ireland</th> </tr> <tr> <th>Year</th> <th>2020/21</th> <th>2021/22</th> <th>2022/23</th> <th>2023/24</th> <th>2024/25</th> </tr> </thead> <tbody> <tr> <td>Number treated with atezolizumab</td> <td>9</td> <td>17</td> <td>17</td> <td>17</td> <td>17</td> </tr> </tbody> </table>	Estimated number of people treated in Northern Ireland						Year	2020/21	2021/22	2022/23	2023/24	2024/25	Number treated with atezolizumab	9	17	17	17	17
Estimated number of people treated in Northern Ireland																			
Year	2020/21	2021/22	2022/23	2023/24	2024/25														
Number treated with atezolizumab	9	17	17	17	17														
4.	<p>Patient Access Scheme Availability</p> <p>(Yes/No)</p> <p>The company (Roche) has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.</p>																		
5.	<p>Infrastructure Requirements</p> <p>Any additional infrastructure costs associated with the introduction of new cancer therapies will be dealt with as part of the routine commissioning process.</p>																		
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients</p>																		
7.	<p>Commissioning arrangements</p> <p>This regimen will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team initially on a cost-per-case (CPC) basis. Thereafter,</p>																		

	<p>numbers of patients who received or are receiving treatment will be reviewed and consideration will be given to moving to recurrent funding to support this regimen</p>
8.	<p>Monitoring arrangements</p> <p>The HSCB cost per case process will generate quarterly reports on the number of applications.</p> <p>HSCB currently routinely reviews quarterly monitoring information in relation to the usage of all recurrently funded specialist cancer drugs across both the Cancer Centre and other Units.</p> <p>The monitoring pro forma will be adapted to capture information in respect of this regimen and this group of patients. This monitoring report is submitted to the Specialist Services Commissioning Team for formal review and comment by the Team.</p>
9.	<p>DoH (NI) Legislative/Policy Caveats</p> <p>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</p>